Zhen Su - 11 Jun 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Zhen Su
Issuer symbol
CTMX
Transactions as of
11 Jun 2025
Net transactions value
$0
Form type
4
Filing time
13 Jun 2025, 16:19:11 UTC
Previous filing
29 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Su Zhen Director C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO /s/ Lloyd Rowland, as Attorney-in-Fact for Zhen Su 13 Jun 2025 0001991642

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Award $0 +38,000 $0.000000 38,000 11 Jun 2025 Common Stock 38,000 $2.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.